Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

被引:0
|
作者
Horesh, Adi [1 ]
Pollack, Rena [1 ,2 ]
Nechushtan, Hovav [1 ,3 ]
Dresner-Pollak, Rivka [1 ,2 ]
Neuman, Tzahi [1 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
关键词
PD-L1; NSCLC; immune checkpoint inhibitors; immune-related adverse events; thyroid; ADVERSE EVENTS; NIVOLUMAB; PEMBROLIZUMAB; ANTIBODIES; TSH; P53;
D O I
10.3389/pore.2023.1610951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [42] Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
    Wang, Yanling
    Yang, Xiaoxuan
    Ma, Jia
    Chen, Shenglan
    Gong, Ping
    Dai, Ping
    HELIYON, 2024, 10 (05)
  • [43] Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction
    Wang, Ai
    Huang, Huijie
    Chen, Yangli
    Zhao, Zhi
    Cong, Li
    Li, Man
    ENDOCRINE, 2025,
  • [44] Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
    Tu, Megan M.
    Ng, Terry L.
    De Jong, Horns C.
    Zuiverloon, Tahlita C. M.
    Fazzari, Francesco G. T.
    Theodorescu, Dan
    BLADDER CANCER, 2019, 5 (02) : 131 - 145
  • [45] Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141
    Ferris, Robert L.
    Blumenschein, George
    Harrington, Kevin
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Kasper, Stefan
    Even, Caroline
    Worden, Francis
    Saba, Nabil F.
    Vokes, Everett
    Ho, Cheryl
    Concha-Benavente, Fernando
    Greenawalt, Danielle
    Jin, Chelsea
    Lynch, Mark
    Tahara, Makoto
    Haddad, Robert
    Monga, Manish
    Kao, Henry
    Gillison, Maura
    CANCER RESEARCH, 2017, 77
  • [46] Factors associated with not receiving first-line (1L) immune checkpoint inhibitor (ICI) treatment among patients (pts) with advanced NSCLC and high programmed cell deathligand 1 (PD-L1) expression: An evaluation by age
    Feliciano, J.
    Wu, N.
    Ge, W.
    Quek, R.
    Gleeson, M.
    Jalbert, J. J.
    Hsu, M. L.
    Harnett, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1075 - S1075
  • [47] Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
    Janning, Melanie
    Kobus, Franca
    Babayan, Anna
    Wikman, Harriet
    Velthaus, Janna-Lisa
    Bergmann, Sonja
    Schatz, Stefanie
    Falk, Markus
    Berger, Lars-Arne
    Boettcher, Lisa-Marie
    Paesler, Sarina
    Gorges, Tobias M.
    O'Flaherty, Linda
    Hille, Claudia
    Joosse, Simon A.
    Simon, Ronald
    Tiemann, Markus
    Bokemeyer, Carsten
    Reck, Martin
    Riethdorf, Sabine
    Pantel, Klaus
    Loges, Sonja
    CANCERS, 2019, 11 (06):
  • [48] Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression
    Li, Yunfeng
    Hu, Maitao
    Li, Lei
    Liu, Sheng
    He, Tingting
    Cheng, Chunyan
    Xu, Mian
    Yin, Xinmin
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (01)
  • [49] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [50] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381